Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

Diabetes, Obesity and Metabolism

Volumn 20, Issue 1, 2018, Pages 224-227

  Petrykiv, Sergei ^a   Laverman, Gozewijn D ^b   de Zeeuw, Dick ^a   Heerspink, Hiddo J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

ACEi; albuminuria; ARB; dapagliflozin; personalized medicine; sodium glucose co transporter 2 inhibitor; type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

ADULT; AGED; ALBUMINURIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE RESISTANCE; DRUG EFFECT; DRUG INHIBITION; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MALE; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DRUG RESISTANCE; HYPERGLYCEMIA; HYPOGLYCEMIA; KIDNEY; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; URINE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZHYDRYL COMPOUNDS; BIOMARKERS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; GLUCOSIDES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85037596198     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13057     Document Type: Article

References (12)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. 2013. Available at www.idf.org/diabetesatlas.
2. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–2539.
3. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia. 1994;37:511–516.
4. Schievink B, de Zeeuw D, Parving HH, Rossing P, et al. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol. 2015;80:678–686.
5. Laverman GD, Navis G, Henning RH, de Jong PE, et al. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002;62:1020–1025.
6. Bos H, Andersen S, Rossing P, De Zeeuw D, et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int. 2000;75(suppl):S32–S37.
7. Heerspink HJ, Perkins BA, Fitchett D, Husain M, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation. 2016;6(134):752–772.
8. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
9. Petrykiv SI, Laverman GD, Zeeuw D, Heerspink HJ. The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.12936.
10. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol. 2009;20:436–443.
11. Petrykiv SI, de Zeeuw D, Persson F, Rossing P, et al. Variability in response to albuminuria lowering drugs: true or random? Br J Clin Pharmacol. 2017 Jun;83(6):1197–1204.
12. Muskiet MH, van Raalte DH, van Bommel EJ, Smits MM, et al. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol. 2015;3:928–929.